Optional product analytics

With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.

DiscoverOutlookToolsDevelopersCompany

← Back to latest report

ABBV · Archive

Read prior published editions, ratings, and price trends. Each row discloses its own analysis date.

2026May

ABBV May 2026 · hold

AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.Latest published research · analyzed 2026-05-08 · historical · sources unverified

Hold

USD 202.71

Unlock 1 more months of research.

The current featured research stays free. An Individual subscription opens the full published archive of prior ratings, commentary, and price history.

Unlock the archive

StockMarketAgent

Methodologyv2.5

Product

Discover Coverage Earnings calendar Stock screener Stock lists Best stocks Markets Outlook Tools Data catalog Pricing Start free

Learn

Methodology Independent research Alternatives Glossary Learning paths Changelog Blog Letters Sample report FAQ

Research / Compare

Alternatives Compare stocks Best stocks Stock screener Stock lists

Developers

Developers API docs Sandbox MCP server

Support Disclaimer Terms of service Privacy policy Editorial guidelines Corrections